AI Stock Analysis - Atricure (ATRC)
Analysis generated November 14, 2025.
AtriCure Inc. (Nasdaq: ATRC) is a leading innovator in treatments for atrial fibrillation (AFib), a common and serious heart rhythm disorder. The company is dedicated to providing solutions through its various product lines, specifically focusing on surgical ablation systems, left atrial appendage (LAA) management solutions, and hybrid approaches for treating advanced and early-stage AFib patients. AtriCure has built a reputation for effective and clinically proven products that significantly improve patient outcomes.
Stock Alerts - Atricure (ATRC)
 |
Atricure | January 15 Price is up by 7.1% in the last 24h. |
|
Atricure | January 13 Business Outlook among employees is down by 11.2% over the last month. |
|
Atricure | January 12 Price is down by -8.5% in the last 24h. |
|
Atricure | January 6 Employee Rating is down by 2.1% over the last month. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Atricure
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 100 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 17,000 | Sign up | Sign up | Sign up |
| Employee Rating | 92 | Sign up | Sign up | Sign up |
| Google Trends | 65 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 7 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,363 | Sign up | Sign up | Sign up |
| Instagram Followers | 1,054 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 390 | Sign up | Sign up | Sign up |
| X Followers | 2,715 | Sign up | Sign up | Sign up |
| X Mentions | 8 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 1,190 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 79 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,326 | Sign up | Sign up | Sign up |
About Atricure
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally.
| Price | $38.41 |
| Target Price | Sign up |
| Volume | 471,830 |
| Market Cap | $1.91B |
| Year Range | $29.24 - $42.41 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Medical & Dental Instruments |
In the news
 |
AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference - SlideshowJanuary 19 - SeekingAlpha |
|
AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 14 - SeekingAlpha |
Ablation Technology Market to Worth Over US$ 16.74 Billion by 2034 | Astute AnalyticaJanuary 21 - GlobeNewswire |
|
Structural Heart Occlusion Devices Market Report 2025: Segments, Share, Regulatory, Reimbursement, Interventions and Forecasts 2015-2036January 20 - GlobeNewswire |
|
AI Diagnostics: The End of the High-Cost Imaging EraJanuary 16 - GlobeNewswire |
|
Left Atrial Appendage Closure Devices Market 2025-2033: Demand Forecast, Regional Insights, Company Profiles – Astute AnalyticaJanuary 15 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 134M | 33M | 101M | -270,000 | 8M | -0.010 |
| Q2 '25 | 136M | 35M | 101M | -6.2M | 730,000 | -0.020 |
| Q1 '25 | 124M | 31M | 93M | -6.7M | -6M | -0.140 |
| Q4 '24 | 124M | 32M | 93M | -16M | -9M | -0.080 |
| Q3 '24 | 116M | 29M | 87M | -7.9M | -940,000 | -0.170 |
Insider Transactions View All
| Noznesky Justin J filed to sell 78,798 shares at $37.3. November 26 '25 |
| WEHRWEIN SVEN filed to sell 34,374 shares at $38. November 26 '25 |
| WEHRWEIN SVEN filed to sell 34,374 shares at $37.3. November 26 '25 |
| Yuen Maggie filed to sell 11,371 shares at $35.7. November 25 '25 |
| Noznesky Justin J filed to sell 83,964 shares at $36.3. September 16 '25 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Gilbert Cisneros |
Jun 9, 25 | Buy | $1K - $15K |
| Josh Gottheimer |
Aug 15, 24 | Buy | $1K - $15K |
| Josh Gottheimer |
Jul 9, 24 | Sell | $1K - $15K |
Read more about Atricure (ATRC) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Atricure
The Market Cap of Atricure is $1.91B.
Currently, the price of one share of Atricure stock is $38.41.
The ATRC stock price chart above provides a comprehensive visual representation of Atricure's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Atricure shares. Our platform offers an up-to-date ATRC stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Atricure (ATRC) does not offer dividends to its shareholders. Investors interested in Atricure should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Atricure are Align Technology, Dentsply, LeMaitre Vascular, iRhythm Technologies, and NovoCure.
